Hologic Rival Cites Abuse in $4 Billion Breast-Screening Sector
- Fujifilm claims ‘sham’ trade case used to thwart competition
- Companies are fighting over 3D-capable mammography systems
Photographer: Steve Gschmeissner/Science Photo Library via Getty Images
This article is for subscribers only.
Hologic Inc.’s control of the market for 3D breast imaging in cancer screening is based on misuse of its patents and litigation, Fujifilm Holdings Corp. said in a lawsuit accusing its bigger rival of antitrust violations.
The global mammography market is projected to be almost $4 billion by 2025, with 3D systems taking a growing share, according to a January 2017 report by Grand View Research. Hologic has 81 percent of the 3D-imaging sector, but faces a challenge from Tokyo-based Fujifilm, which received Food and Drug Administration approval in January 2017 to sell its 3D mammography system.